Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $42.60

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $42.60.

Several equities analysts have weighed in on the company. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Truist Financial lifted their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. HC Wainwright increased their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Finally, Piper Sandler reissued a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This trade represents a 15.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.30. This represents a 13.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Louisiana State Employees Retirement System increased its holdings in shares of Collegium Pharmaceutical by 1.9% in the 2nd quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock worth $531,000 after buying an additional 300 shares during the last quarter. SummerHaven Investment Management LLC increased its stake in Collegium Pharmaceutical by 1.3% in the second quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company’s stock valued at $1,120,000 after acquiring an additional 452 shares during the last quarter. TD Private Client Wealth LLC increased its stake in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares during the last quarter. Foundry Partners LLC raised its position in Collegium Pharmaceutical by 3.3% during the third quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 509 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Collegium Pharmaceutical by 1.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock worth $1,137,000 after purchasing an additional 535 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL opened at $30.50 on Friday. The business has a 50-day moving average price of $34.94 and a two-hundred day moving average price of $34.62. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical has a 1-year low of $25.21 and a 1-year high of $42.29. The stock has a market capitalization of $983.63 million, a P/E ratio of 13.15 and a beta of 0.95.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.